Inclusion Criteria:

- Histologically or cytologically confirmed NSCLC.

- ECOG Performance Status 0-2.

- No previous treatment with Docetaxel.

- Measurable Disease.

- Brain metastases that have been treated with radiotherapy should be stable and
asymptomatic.

- Adequate liver kidney and bone marrow function.

- Patients must be able to understand the nature of this study and give written
informed consent.

Exclusion Criteria:

- Active cardiac disease: unstable angina or onset of angina within last 3 months,
myocardial infarction within 6 months, congestive heart failure > class II, cardiac
ventricular arrhythmias requiring anti-arrhythmic therapy.

- Women who are pregnant or lactating.

- Unknown HIV, chronic hepatitis B or chronic hepatitis C infections.

- Serious neurologic or psychiatric disease.

- Second primary malignancy within the past 5 years, except nonmelanomas skin cancer or
in situ carcinoma of the cervix.

- Active uncontrolled infection.